Rigel Pharmaceuticals (RIGL) Invested Capital (2010 - 2026)

Rigel Pharmaceuticals' Invested Capital history runs 17 years deep, the most recent figure standing at $429.8 million for Q1 2026.

• In Q1 2026, Invested Capital rose 1187.41% year-over-year to $429.8 million; the TTM figure through Mar 2026 stood at $429.8 million (up 1187.41% YoY), while the FY2025 annual figure was $421.3 million, up 3889.51% from the prior year.
• Invested Capital was $429.8 million for Q1 2026 at Rigel Pharmaceuticals, up from $421.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $429.8 million in Q1 2026 to a low of -$31.8 million in Q3 2023.
• Historically, Invested Capital has averaged $55.8 million across 5 years, with a median of -$13.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Invested Capital sank 664.62% in 2023, then surged 3889.51% in 2025.
• A 5-year view of Invested Capital shows it stood at -$13.6 million in 2022, then slumped by 57.28% to -$21.4 million in 2023, then surged by 149.31% to $10.6 million in 2024, then soared by 3889.51% to $421.3 million in 2025, then rose by 2.01% to $429.8 million in 2026.
• The last three Invested Capital figures came in at $429.8 million (Q1 2026), $421.3 million (Q4 2025), and $147.4 million (Q3 2025), per Business Quant data.